The Miami Stem Cell Therapy Podcast

Today’s episode is a little different. Instead of focusing on the science itself, we’re looking at a trend among the physicians who study it: a growing number of regenerative medicine specialists are actively seeking out structured education on Muse cells.
 
Why now? A few things seem to be driving it. First, the published research base has simply grown. Since Professor Mari Dezawa and colleagues first characterized Muse cells in 2010, the volume of peer-reviewed literature covering their biology, their mechanism, and early clinical trial data has expanded steadily across specialties including cardiology, neurology, and dermatology. That gives physicians an actual body of evidence to study, rather than relying on marketing claims or anecdotal reports.
 
Second, patient interest is rising. As public awareness of regenerative medicine grows, physicians report fielding more direct questions from patients about biologic therapies, Muse cell-based approaches included. That creates real demand for physicians to be able to explain, accurately, what is and isn’t established about a given therapy.
 
Third, and this one is important: terminology in this space isn’t always tightly regulated. Products described using similar language can differ substantially in origin, manufacturing standard, and scientific validation. So part of physician education now involves learning to distinguish an authentic, well-documented protocol from a similarly named product that may not have the same evidence behind it.
 
So what does this education actually look like in practice? A lot of it happens at regenerative medicine conferences, which give physicians direct access to researchers presenting original data and a chance to ask detailed technical questions. Beyond that, many physicians build an ongoing habit of tracking peer-reviewed literature as it’s published, across the relevant specialty journals, rather than treating a single training session as sufficient. And increasingly, physician education includes direct review of a specific manufacturer’s protocol documentation: how the cells are sourced, isolated, validated, and quality-tested before clinical use.
 
That last point connects to a theme that comes up again and again in this space: standardization. Consistent isolation methods, validated potency and purity testing, and reproducible manufacturing processes matter because published research is generated using specific, validated protocols. A product using similar terminology but a different or unvalidated protocol may not produce comparable results, even if it sounds the same on paper.
 
Ultimately, this translates into better patient conversations. Physicians who’ve done the work of reviewing the underlying literature are better positioned to set accurate expectations, explaining clearly which applications remain investigational, which trial phases have been reached, and what a given patient should realistically expect.
 
Groups like STEMS Health, a regenerative medicine practice in Miami Beach, Florida, reflect this broader trend, prioritizing ongoing education grounded in peer-reviewed research and manufacturing transparency. As with every episode, this content is for general educational purposes only and isn’t medical advice. Any regenerative medicine procedures mentioned may be considered investigational or not FDA approved for certain conditions, so speak with a licensed healthcare provider about what’s appropriate for you.
 
That wraps up today’s episode. Thanks for listening.

If you’ve listened to this podcast before, you’ve probably heard us mention a property called tissue homing. Today, let’s actually unpack what that means and how it works.
 
In cell-based research, homing refers to the ability of cells, once administered, to migrate toward a specific site in the body rather than distributing randomly or getting stuck somewhere unrelated to the injury. That distinction matters more than it might sound. Standard mesenchymal stem cells, for instance, are known to become passively trapped in the lungs after intravenous injection, regardless of where the actual injury is. A cell type capable of active, targeted homing offers a more direct path to the treatment site, without needing surgical delivery.
 
Muse cells, identified by Professor Mari Dezawa and colleagues, are the property most consistently discussed in this context. Here’s the mechanism: when tissue is damaged, anywhere in the body, it releases a lipid signaling molecule called sphingosine-1-phosphate, or S1P. Researchers describe it as a kind of universal distress signal, with local levels rising at the site of damage, whether that damage comes from a heart attack, a spinal cord injury, or radiation exposure. Muse cells express a specific receptor for that signal, called S1PR2, which allows circulating cells to detect elevated S1P and travel toward it. In several animal studies, differentiated cells that arrive this way have gone on to integrate into existing tissue structures, including neuronal circuits studied in spinal cord and brain research.
 
This matters to researchers for a couple of practical reasons. Because the S1P signal is released by damaged tissue generally, rather than being specific to one organ, the homing mechanism has been studied across cardiac, neurologic, dermatologic, and gastrointestinal research, all building on the same underlying biology rather than starting from separate premises each time. And because some injury sites are diffuse, hard to access, or simply not good candidates for direct injection, a cell type that can be delivered intravenously and still find its way to the target offers a practical advantage.
 
So how do scientists actually verify this happens? In the lab, researchers typically label Muse cells with fluorescent or luminescent markers before administering them, then track their location over time to confirm whether, and how much, they accumulate at the injury site rather than elsewhere. Some studies have gone further, using receptor-blocking agents to show that when the S1PR2 pathway is inhibited, homing and the associated tissue repair drop off significantly, which is fairly strong evidence for how central that mechanism actually is.
 
A couple of caveats are worth mentioning. Not every infused Muse cell reaches the injury site. Published research indicates only a portion do, with the rest distributed elsewhere or cleared through normal processes. And this homing behavior does appear to be a distinguishing feature of Muse cells specifically. Standard mesenchymal stem cells that lack the SSEA-3 marker have shown less effective homing through this same pathway in research studies.
 
STEMS Health, a regenerative medicine practice based in Miami Beach, Florida, follows this line of research as part of tracking how the science develops. As always, this is general educational content, not medical advice, and related procedures may be investigational or not yet FDA approved. Consult a licensed healthcare provider for guidance specific to you.
 
Thanks for listening, and we’ll see you in the next episode.

Today we’re zooming out a bit to talk about where regenerative medicine as a field seems to be headed, and why one particular cell type, the Muse cell, keeps coming up in that conversation.
 
Over the past decade, regenerative medicine research has been moving away from one-size-fits-all protocols and toward approaches that account for differences between patients: the type of injury, the stage of disease, and individual biology. That shift has been driven partly by better diagnostic imaging and biomarker tools, which let researchers get a clearer picture of who might respond to a given treatment, and when.
 
Cell-based therapies sit right in the middle of that trend, but their usefulness depends heavily on whether a given cell type can actually be delivered precisely and consistently. This is where Muse cells, first identified by Professor Mari Dezawa, draw particular interest. Because they can detect an injury signal called sphingosine-1-phosphate through a receptor called S1PR2, they’re able to be given intravenously and still concentrate at a site of tissue damage, whether that’s the heart, the spinal cord, or the skin. That’s a meaningful difference from therapies that require direct injection or surgical placement at a specific location.
 
Still, there are real open questions researchers are working through before this potential becomes an established clinical reality. How many cells are actually needed for a given condition, and does repeated dosing outperform a single administration? How long do differentiated cells persist in the body, and is any reparative effect sustained over years rather than months? Do promising early results in one condition, like heart attack recovery, generalize to other organ systems? Can manufacturing of a frozen cell product scale up to meet demand across multiple treatment centers? And how will regulators evaluate a therapy with such a broad range of potential applications?
 
Researchers also tend to frame this work as part of a bigger-picture shift toward personalized regenerative medicine, one where diagnostics help determine which patients are likely to benefit from a given intervention, and where protocols developed in one specialty, say cardiology, inform work happening in neurology, orthopedics, or dermatology. It’s a similar logic to what’s already played out in precision oncology, where biomarker-driven treatment selection has become standard practice.
 
It’s worth being direct about the current state of things, though. Personalization in this context mostly describes a research direction, not an established, individualized treatment model. Most published clinical trials still use standardized dosing for a given condition. And there’s no evidence yet that Muse cells require the kind of donor matching used in organ transplants, though that’s an area of continued study rather than settled practice.
 
Groups like STEMS Health, a regenerative medicine practice in Miami Beach, Florida, follow this research as part of understanding where the field may be going next. As always, this is general information, not medical advice, and any regenerative procedures discussed may be investigational or not yet FDA approved for certain conditions. 
 
Thanks for listening, and we’ll catch you next time.

Let’s talk today about a distinction that comes up often in stem cell research: the difference between cells that are engineered to become pluripotent, and cells that are simply found that way in the body already.
 
Most of the attention-grabbing stem cell science over the past two decades has centered on induced pluripotent stem cells, or iPSCs, first developed by Shinya Yamanaka. Making an iPSC involves taking an adult cell and introducing specific transcription factors to push it back into an embryonic-like state. It’s a clever workaround for the ethical and supply issues tied to embryonic stem cells, but it introduces its own technical challenges, including the risk that if any of those reprogrammed cells remain undifferentiated after transplant, they can form a type of tumor called a teratoma. Embryonic stem cells carry similar tumorigenicity concerns of their own.
 
Muse cells take a different path entirely. They were first identified in 2010 by Professor Mari Dezawa and colleagues, and they occur naturally in adult tissue, including bone marrow, fat tissue, and peripheral blood. Researchers identify them using a surface marker called SSEA-3, and because they already exist in the body in this state, isolating them is a matter of sorting cells that are already there, rather than reprogramming or engineering anything. No viral vectors, no transcription factor reprogramming, no embryonic tissue involved.
 
That distinction turns out to matter for a few practical reasons researchers care about. First, tumorigenicity: published animal studies to date haven’t shown Muse cells forming teratomas, in contrast to the documented risk associated with iPSCs and embryonic stem cells. Second, manufacturing complexity: because there’s no reprogramming or differentiation-induction step required, the production process is simpler than what’s needed for engineered pluripotent cells. Third, immune compatibility: Muse cells express a marker called HLA-G, which is associated with immune tolerance, similar to mechanisms seen in placental tissue. Researchers have studied whether that property might reduce the need for donor matching or immunosuppressive drugs in certain contexts. And fourth, there’s the homing behavior we’ve covered on this show before, the ability of Muse cells to travel to an injury site through a signaling pathway involving sphingosine-1-phosphate and a receptor called S1PR2, a property not shared by standard mesenchymal stem cells to the same degree.
 
Put together, natural origin, an apparent absence of tumor formation in current studies, and built-in injury homing make Muse cells a distinct subject of study compared to both conventional mesenchymal stem cells and engineered pluripotent cell types. That’s part of why groups like STEMS Health, a Miami Beach-based regenerative medicine practice, keep a close eye on this area of the literature.
 
Thanks for tuning in, and we’ll see you next time.

Welcome back to the show. Today we’re taking a closer look at a naturally occurring stem cell that keeps showing up in research papers across a surprising range of medical specialties: the Muse cell, discovered in 2010 by Professor Mari Dezawa and her colleagues at Tohoku University.
What makes this cell type so interesting to scientists isn’t just that it’s pluripotent-like, meaning it has the potential to become many different cell types. It’s that Muse cells appear to know where to go. They carry a receptor called S1PR2, which detects a signaling molecule released by damaged tissue, called sphingosine-1-phosphate. When tissue anywhere in the body is injured, Muse cells circulating in the blood can sense that signal and travel toward it. That mechanism isn’t specific to any one organ, which helps explain why researchers in neurology, cardiology, orthopedics, pulmonology, and dermatology have each, independently, started investigating the same cell type.
In neurology, scientists have looked at how Muse cells behave after stroke and spinal cord injury. In cardiology, researchers have studied whether these cells home to heart tissue after a heart attack, and whether they can differentiate into the kinds of cells that make up heart muscle and blood vessels. Some of that cardiology work has moved into early-phase human trials, largely in Japan, alongside similar early trials for conditions like ALS, spinal cord injury, and a genetic skin condition called epidermolysis bullosa. Orthopedic and pulmonary research remains earlier stage, still largely limited to laboratory and animal studies.
It’s worth pausing here to be clear about what all of this does and doesn’t mean. Early-phase clinical trials are designed to answer questions about safety and dosing. They are not the same as full regulatory approval, and no Muse cell-based product currently holds that kind of approval for routine use in the United States. Anything you hear described in the research literature should be understood as investigational unless a specific regulatory clearance is cited.
So why does it matter that so many different fields are studying the same cell independently? Because when neurologists, cardiologists, and dermatologists are all seeing similar patterns, it strengthens the overall case for the underlying biological mechanism, even while each specialty is still working through its own condition-specific questions. Researchers tend to track a similar set of themes across this work: how precisely the cells home to an injury site, whether they reliably turn into the right kind of tissue once they arrive, how dosing and repeat administration affect outcomes, and what the long-term safety picture looks like.
Organizations like STEMS Health, a regenerative medicine practice based in Miami Beach, Florida, follow this research closely as part of staying current on where the science stands. If you’re curious about Muse cell research, it’s a field worth watching, and one that’s likely to keep generating new questions for years to come.
That’s it for today’s episode. Thanks for listening.

How Dezawa MuseCells Became a Global Conversation in Regenerative Medicine
Drs. Ankeet Choxi and Jarred Mait at STEMS Health often get a version of this question from patients who are new to regenerative medicine. If Muse cells are such a big deal, why did it take this long for me to hear about them? The answer is actually a pretty good sign, because it shows this technology grew the slow, credible way, not through a marketing push.
It started in two thousand ten, when Professor Mari Dezawa's team published the original discovery in the Proceedings of the National Academy of Sciences, one of the most respected scientific journals in the world. That single publication led to more research, including additional papers and a detailed methodology paper in twenty thirteen that let other labs reproduce her work. Over time, Dezawa herself authored more than two hundred peer reviewed papers, and her research earned real institutional recognition, including Japan's Commendation for Science and Technology and a fellowship in the U.S. National Academy of Inventors.
From there, the science expanded well beyond its original context. Researchers began studying Muse cells in neurology, cardiovascular medicine, orthopedics, and pulmonary conditions, moving through preclinical work and into Phase two human trials in Japan. That kind of cross disciplinary interest does not happen with a discovery that does not hold up under scrutiny. It happens when independent research groups keep finding something worth studying.
Physician education followed a similar path. Conferences and continuing education programs gave doctors a chance to engage directly with the underlying research, ask questions about manufacturing and patient selection, and bring that understanding back into their own practices. That is a very different growth pattern than a product that spreads through advertising alone.
Only in the last few years has patient awareness really caught up to the research. And that creates a new challenge. As more people search for information about Muse cells, more products and clinics have started using similar language, which makes it more important than ever to understand where a given treatment actually comes from.
Drs. Choxi and Mait see this as a good problem to have. More awareness means more patients asking better questions, and more clinics being held to a higher standard when they talk about this technology. The story is still being written too, since research keeps expanding into new conditions and new applications every year. If you want to understand how more than a decade of research applies to your own situation, reach out to STEMS Health and start a real conversation with our team.

Why Authentic Dezawa MuseCells Matter More Than Ever
This is one of the most important conversations Doctors Ankeet Choxi and Jarred Mait have with patients at STEMS Health, because it is also one of the most misunderstood. As Muse cells have become more well known, the number of products and clinics using that name has grown right along with it. And here is the uncomfortable truth. Using the name does not automatically mean a product is the real thing.
Authentic Dezawa MuseCells refers specifically to cells isolated and manufactured according to Professor Mari Dezawa's validated protocols, using defined markers and culture conditions that have actually been published and peer reviewed. That is a scientific standard, not a marketing label. A product can call itself a Muse cell and still be produced through a completely different process, with different sourcing, different quality control, and none of the same published research behind it.
This matters because the traits that make Muse cells valuable in the first place, their stress tolerance, their broader differentiation ability, their tendency to migrate toward damaged tissue, and their strong safety profile, are specific to cells isolated through that validated process. If a product skips that process, there is no scientific basis for assuming it shares those same characteristics, no matter how similar the marketing sounds.
So what should you actually do with this information? Ask direct questions before committing to any treatment. Is this based on Dezawa's specific validated protocol? What is the manufacturing source, and what quality control standards govern it? What does the actual published research say about this exact product, not just the cell type in general? A provider who knows the answers, and is willing to share them, is telling you something important. So is a provider who cannot.
This is also where physician expertise comes in. A physician who understands the underlying research is far better equipped to set realistic expectations and match you with the right treatment, rather than presenting early stage research as a guaranteed result. That is exactly the kind of conversation Drs. Choxi and Mait aim to have with every patient who walks through the door.
As this field continues to grow, that gap between authentic, validated products and everything else using similar language is not going away on its own. If anything, growing patient interest tends to increase the incentive for products to borrow recognizable scientific language, whether or not the manufacturing behind them actually earns it. That is not a reason to be discouraged, it is just a reason to ask better questions before you commit to anything. If you want a straight answer about what you are actually being offered, reach out to STEMS Health and talk with our team.

Understanding the Dezawa Protocol: Why Standardization Matters
Patients at STEMS Health often ask Drs. Ankeet Choxi and Jarred Mait a version of the same question. If Muse cells are so rare, how does anyone actually isolate them consistently? The answer comes down to something called the Dezawa Protocol, and it is a bigger deal than most people realize.
The Dezawa Protocol is the validated laboratory methodology developed by Professor Mari Dezawa's team for identifying and isolating Muse cells from a broader population of mesenchymal stem cells. It is not a product. It is a process, and that distinction matters enormously in medicine. A discovery is only as useful in the clinic as the method used to reproduce it reliably, batch after batch, lab after lab.
Here is why that is such a challenge in the first place. Muse cells make up a small percentage of any given stem cell culture. You cannot just look at cells under a microscope and pick out the right ones. The protocol solves this by relying on specific, defined markers, most notably something called SSEA three, a marker linked to pluripotent like cells. It also specifies the exact culture conditions needed to preserve the cells' natural stress tolerant characteristics through processing. Without that level of specificity, one lab's version of a Muse cell could end up meaningfully different from another lab's version, even if both used the same name.
This is also where things shift from a research protocol into a manufacturing standard. Producing cells for actual clinical use means adding sterility standards, documentation, and quality control checkpoints at every stage, well beyond what is needed to publish an academic paper. That layer of oversight is what allows a manufactured product to stay tied to the same research base it claims to represent, rather than drifting into something else entirely over time.
This is exactly why Doctors Choxi and Mait encourage patients to ask specific questions before choosing a treatment. Is this based on Dezawa's actual validated protocol, or something using similar language without the same process behind it? What quality control measures are actually in place? These are not rhetorical questions. The answers tell you whether a treatment is grounded in reproducible science, or just borrowing familiar terminology.
Manufacturing consistency will not answer every question about whether a treatment is right for you, but it is one of the clearest signals of scientific credibility available. Protocols like this one are not necessarily fixed forever either. As research continues, methodologies are sometimes refined to address new questions about long term consistency and stability, which is a normal part of how any area of regenerative medicine matures over time. If you want to understand exactly how this applies to a treatment you are considering, reach out to STEMS Health and talk with our team directly.

Why Dezawa MuseCells Are Different: Understanding the Science
At STEMS Health, Drs. Ankeet Choxi and Jarred Mait get asked this question in almost every consultation. Aren't Muse cells just mesenchymal stem cells with a different name? The short answer is no, and the difference actually matters quite a bit.
Mesenchymal stem cells, or MSCs, are one of the most widely used cell types in regenerative medicine. They come from places like bone marrow and fat tissue, and they mostly work through signaling, calming inflammation and encouraging the surrounding tissue to repair itself. For a long time, researchers treated a batch of MSCs as one uniform population. But Professor Mari Dezawa's research showed that is not quite accurate. Hidden inside those MSC cultures is a smaller subpopulation of cells that behave very differently, and that subpopulation is what we now call Muse cells.
The first thing that sets them apart is stress tolerance. In the lab, Muse cells can survive conditions that would normally kill a cultured cell, things like oxygen deprivation, harsh enzymatic processing, and extended nutrient starvation. That resilience is part of what makes them consistent to work with during manufacturing.
The second big difference is differentiation capacity. Standard MSCs generally turn into a narrower set of cell types, mostly bone, cartilage, and fat. Muse cells have been shown in published research to differentiate into cell types representing all three embryonic germ layers, a trait usually associated with pluripotent stem cells. And unlike embryonic stem cells or induced pluripotent stem cells, Muse cells occur naturally in the body and do not require genetic reprogramming, which is part of why published research has not shown the tumor risk associated with some other pluripotent cell types.
Then there is tissue homing. This is one of the more remarkable behaviors described in the literature. When introduced into the body, Muse cells appear to migrate toward damaged tissue on their own, responding to signals released by the injury itself, rather than distributing randomly. Researchers are still studying exactly how significant this is for different conditions, but it is one of the main reasons this cell type continues to draw so much scientific attention.
None of this means every product labeled as a Muse cell is the same. Isolating this specific subpopulation requires a validated process, and not every manufacturer follows it. That is exactly why Drs. Choxi and Mait spend time walking patients through where their specific product actually comes from, rather than relying on a name alone.
If you want to understand how these differences apply to your own treatment options, reach out to STEMS Health and set up a real conversation with our team.

Who Is Professor Mari Dezawa? The Scientist Behind Dezawa MuseCells
If you have spent any time researching regenerative medicine, you have probably come across the name Mari Dezawa. At STEMS Health, Drs. Ankeet Choxi and Jarred Mait hear the same question all the time. Who is this person, and why does her name show up on so much of the research behind Muse cells?
Professor Dezawa is a physician and neuroscientist based at Tohoku University in Japan. She did not start out as a stem cell researcher. She trained in clinical medicine, then spent years studying neural regeneration before her work eventually led her into cell biology. That path matters, because it means the science behind Muse cells was built by someone who spent years in clinical practice first, not someone who jumped straight into a lab with a theory to prove.
The discovery itself came out of an unexpected observation. In two thousand three, a member of her lab was working with cultured bone marrow stem cells and noticed a small group of cells behaving differently than the rest. Instead of dismissing it, Dezawa and her team investigated further. That investigation eventually led to identifying a distinct subpopulation of cells that could survive conditions that would normally destroy a cultured cell, and that showed the ability to differentiate into multiple cell types. She named them Muse cells, short for multi lineage differentiating stress enduring cells, and published the discovery in the Proceedings of the National Academy of Sciences in twenty ten.
Since then, her research has continued to expand. She has authored more than two hundred peer reviewed papers, and her work has been recognized with honors including Japan's Commendation for Science and Technology and a fellowship in the U.S. National Academy of Inventors. Her lab also published a detailed methodology paper in twenty thirteen, laying out exactly how Muse cells should be isolated and identified, so that other researchers around the world could reproduce the findings consistently.
Why does any of this matter if you are a patient, not a scientist? Because the strength of a regenerative therapy comes down to the strength of the science behind it. Knowing that Muse cells were identified through careful, peer reviewed research, by a physician with decades of clinical background, gives you a much clearer picture of what you are actually being offered when a clinic mentions this technology.
At STEMS Health, Drs. Choxi and Mait often walk patients through exactly this kind of background before ever discussing treatment options, because understanding where a therapy comes from is part of understanding whether it is right for you. If you want to know more about how Professor Dezawa's research applies to your specific situation, the next step is a real conversation with our team, not just a podcast. Reach out to STEMS Health to learn more.